MedTrace Logo

European iNvestigation of SUrveillance After Resection for Esophageal Cancer

NCT03461341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2020-03-26

No results posted yet for this study

Summary

The ENSURE study will comprise two phases.

Phase 1: European multicenter survey of surveillance protocols after esophageal cancer surgery

ENSURE questionnaire will be circulated to representatives from participating European countries.

Phase 2: European multicenter retrospective observational study of the impact of postoperative surveillance protocols on oncologic outcome and HR-QL

Phase 2 will constitute a retrospective observational study of patients undergoing treatment with curative intent for esophageal cancer at participating Centers from June 2009 to June 2015.

Conditions

  • Esophageal Cancer
  • Metastatic Cancer
  • Recurrent Esophageal Cancer
  • Chemoradiation
  • Chemotherapy
  • Radiation
  • Surgery

Interventions

OTHER

High intensity postoperative oncologic surveillance

High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).

Sponsors & Collaborators

  • St Mary's Hospital, Paddington, London

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • St. James's Hospital, Ireland

    lead OTHER

Principal Investigators

  • John V Reynolds, MD FRCS · St. James's Hospital, Dublin, Ireland

  • George B Hanna, PhD FRCS · St. Mary's Hospital, London, United Kingdom

  • Magnus Nilsson, MD FRCS · Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-01
Primary Completion
2015-06-01
Completion
2019-04-01

Countries

  • Ireland
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03461341 on ClinicalTrials.gov